Sign In
Buy CAPR
$25.33
-0.680 (-2.61%)
At Close: Jun 10, 2026
Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
08:05pm, Wednesday, 10'th Aug 2022 GlobeNewswire Inc.
-First Patient Treated in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy-
AdaptHealth Corp. (AHCO) Q2 Earnings and Revenues Miss Estimates
12:25pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -35.71% and 0.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ICU Medical (ICUI) Q2 Earnings and Revenues Lag Estimates
10:15pm, Monday, 08'th Aug 2022 Zacks Investment Research
ICU Medical (ICUI) delivered earnings and revenue surprises of -18.93% and 1.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Reports Q1 Loss, Lags Revenue Estimates
03:05pm, Friday, 05'th Aug 2022 Zacks Investment Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -250% and 0.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10
12:00pm, Wednesday, 03'rd Aug 2022 GlobeNewswire Inc.
Company to Host Conference Call, August 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, August 10, 2022, at 4:30 p.m. ET
Capricor Therapeutics to Present Second Quarter 2022 Financial Results and Recent Corporate Update on August 10
08:00am, Wednesday, 03'rd Aug 2022
Company to Host Conference Call, August 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, August 10, 2022, at 4:30 p.m. ET
Capricor Therapeutics Announces First Patient Dosed in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy
01:15pm, Tuesday, 19'th Jul 2022 GlobeNewswire Inc.
-Double-Blind, Randomized, Placebo-Controlled HOPE-3 Clinical Trial Designed to Enroll approximately 70 Patients-
More Than $27 Million Bet On Seres Therapeutics? 4 Penny Stocks Insiders are Buying
12:25pm, Friday, 08'th Jul 2022 Benzinga
U.S. stock futures traded lower this morning on Friday ahead of jobs report for june. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates
Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference
01:00pm, Friday, 17'th Jun 2022 GlobeNewswire Inc.
Results to be Presented in Late-Breaking Session Results to be Presented in Late-Breaking Session
Results to be Presented in Late-Breaking Session Results to be Presented in Late-Breaking Session
Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference
09:00am, Wednesday, 18'th May 2022
SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treat
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marban on Q1 2022 Results - Earnings Call Transcript
09:02pm, Tuesday, 10'th May 2022
Capricor Therapeutics, Inc. (NASDAQ:CAPR ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marban - Co-Founder, Preside
Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10
12:30pm, Tuesday, 03'rd May 2022 GlobeNewswire Inc.
Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET
Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10
08:30am, Tuesday, 03'rd May 2022
Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET
7 Undervalued Penny Stocks With Major Upside
07:34pm, Tuesday, 29'th Mar 2022
Each of these penny stocks has proven momentum throughout 2022 and major upside on top of the returns through the the first quarter. The post 7 Undervalued Penny Stocks With Major Upside appeared firs
